No Data
Home Healthcare Inflation Is Stubbornly High -- WSJ
FDA Approval Race: AI-Powered Innovations Reshape the Healthcare Landscape
Northland Securities Maintains Spectral AI(MDAI.US) With Buy Rating, Maintains Target Price $6
Northland Securities Sticks to Their Buy Rating for Spectral AI (MDAI)
Spectral AI Completes Data Analytics for U.S. Burn Pivotal Study, Strengthening DeepView System Validation
Spectral AI Completes Pediatric Enrollment In Emergency Departments For U.S. Burn Pivotal Study; Company Will Pursue A De Novo Classification From The U.S. FDA For Use Of The DeepView System And Expects To Submit The Request In The First Half Of 2025
Lnova : Love $Spectral AI (MDAI.US)$ long hold